Drug-eluting Bead Chemoembolization for the Treatment of Nonresectable Hepatic Carcinoma in Dogs: A Prospective Clinical Trial

CP Rogatko , C Weisse , Tobias Schwarz, AC Berent, MA Diniz

Research output: Contribution to journalArticlepeer-review

Abstract

Abstract
Background: Effective treatment options for nonresectable hepatic carcinoma
(HC) in dogs are limited.
Hypothesis/Objective: Objectives were to report outcomes, complications, and
tumor responses via computed tomography (CT) assessment after drug-eluting bead
transarterial chemoembolization (DEB-TACE) for nonresectable HC in dogs. The
authors hypothesized that major complications would be uncommon and short-term
CT assessment would demonstrate stable disease or partial response.
Animals: Client-owned dogs (n = 16) with nonresectable HC.
Methods: Prospective, single-arm clinical trial. Drug-eluting bead transarterial
chemoembolization was performed to varying levels of blood flow stasis. Computed
tomography imaging was compared before and approximately 12 weeks after initial
treatment.
Results: Drug-eluting bead transarterial chemoembolization was successfully administered
in all attempts. Based on percent change in elliptical tumor volume response
(mL), stable disease (8/13; 62%) was the most common outcome followed by partial
response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days
(range, 39-125) after initial treatment. Median tumor volume (mL) after DEB-TACE
decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications
consistent with postembolization syndrome occurred after 7/27 (26%) treatments.
Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment-induced death after
2/27 (7%) treatments. Median survival time after treatment was 337 days (range,
22-1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly
shorter median survival time (126 days; range, 46-337) than those dogs without prior
history of weight loss (582 days; range, 22-1061).
Conclusions: Drug-eluting bead transarterial chemoembolization for nonresectable
HC is a feasible procedure, which promoted stable disease or partial response in 85%
of dogs in this study sample.
Original languageEnglish
Pages (from-to)1487-1495
JournalJournal of Veterinary Internal Medicine
Volume35
Early online date6 May 2021
DOIs
Publication statusE-pub ahead of print - 6 May 2021

Keywords

  • DEB
  • Doxorubicin
  • Interventional radiology
  • Liver
  • TACE

Fingerprint

Dive into the research topics of 'Drug-eluting Bead Chemoembolization for the Treatment of Nonresectable Hepatic Carcinoma in Dogs: A Prospective Clinical Trial'. Together they form a unique fingerprint.

Cite this